FindTrial
Sign In

An ancillary study of (a randomized phase 2 study of TS-1 versus CDDP+VNR for adjuvant therapy in patients with non-small cell lung cancer)-exploratory study of cost-effectiveness

An ancillary study of (a randomized phase 2 study of TS-1 versus CDDP+VNR for adjuvant therapy in patients with non-small cell lung cancer)-exploratory study of cost-effectiveness - LOGIK1702-B

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000042698
Enrollment
110
Registered
2020-12-09
Start date
2021-01-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer

Interventions

None listed

Sponsors

Clinical Research Support Center Kyushu
Lead Sponsor
Lung Oncology Group in Kyushu (LOGIK)
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients enrolled in LOGIK1702 2) Patients providing the written informed consent.

Exclusion criteria

Exclusion criteria: Nothing particular

Design outcomes

Primary

MeasureTime frame
Cost-minimization analysis, cost- effectiveness ratio (CER), incremental cost-effectiveness ratio (ICER), cost-utility ratio, incremental cost-utility ratio—

Countries

Japan

Contacts

Public ContactTomoshi Tsuchiya

Toyama University Hospital Respiratory surgery

tomoshi@nagasaki-u.ac.jp076-434-7371

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026